DRAXXIN® and EXCEDE® Receive FDA Approval to Treat Foot Rot in Cattle

NEW YORK (Nov. 4, 2008) – Dairy and beef producers can now treat foot rot with the most convenient, single-dose anti-infectives on the market – DRAXXIN® (tulathromycin) Injectable Solution and EXCEDE® (ceftiofur crystalline free acid) Sterile Suspension. In addition to treating bovine respiratory disease (BRD), DRAXXIN and EXCEDE are approved to effectively treat foot rot in cattle.

Foot rot is a common cause of cattle lameness that can affect just a few animals, or according to the “Beef Cattle Handbook,” 10 to 15 percent of a herd.1 And high intensity dairy operations have reported foot rot incidence rates up to 25 percent.2 Along with management techniques like clean and dry bedding and pens, foot rot management typically includes treating affected cattle with anti-infectives such as DRAXXIN or EXCEDE.

Extended therapy in a single dose for dairy cows and calves

EXCEDE already provides broad-spectrum efficacy against BRD, and with its unique base of ear administration, now treats foot rot associated with Fusobacterium necrophorum and Porphyromonas levii. With the advantages of zero milk discard, EXCEDE’s extended therapy in a single dose delivers profitability to dairy producers with savings in time, labor and stress on dairy cows.

For dairy calves up to 20 months of age, DRAXXIN is the only anti-infective approved for the treatment of BRD caused by all four major pathogens, including Mycoplasma bovis, and pink eye. It now lends itself to greater efficiency options with its added label claim for the treatment of foot rot.

Economic and effective treatment for beef producers

DRAXXIN is also the only anti-infective approved for the treatment and control of bovine respiratory disease (BRD), or calf pneumonia, in high-risk beef cattle. Working with a cattle’s immune system to treat disease without repeated administration, DRAXXIN is the only single-dose product available for BRD control and treatment associated with all four major pathogens, including Mycoplasma bovis, and now treats foot rot. DRAXXIN also treats pink eye associated with Moraxella bovis.

For beef cattle, EXCEDE provides extended therapy in a single-dose treatment for BRD and foot rot. Just a single dose of broad-spectrum EXCEDE works with the immune system of cattle without repeated administration to give an economically viable and effective treatment choice to producers.

DRAXXIN is not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal. DRAXXIN has a pre-slaughter withdrawal time of 18 days.

Visit draxxin.com for full prescribing information.

As with all drugs, the use of EXCEDE Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug. Though safe in cattle when properly administered, inadvertent intra-arterial injection in the ear is possible and is fatal. EXCEDE has a pre-slaughter withdrawal time of 13 days.

Visit excede.com for full prescribing information.

Pfizer Inc. (NYSE: PFE), the world’s largest research-based pharmaceutical company, is a world leader in discovering and developing innovative animal vaccines and prescription medicines. Pfizer Animal Health is dedicated to improving the safety, quality and productivity of the world’s food supply by enhancing the health of livestock and poultry; and in helping companion animals live longer and healthier lives. For additional information on Pfizer Animal Health and its portfolio of animal products, visit PfizerAH.com.

###

1 Lincoln SD. Infectious foot rot of cattle. In: Beef cattle handbook. Extension Beef Cattle Resource Committee and the University of Wisconsin-Extension, Cooperative Extension. Available at: http://www.iowabeefcenter.org/pdfs/bch/03225.pdf. Accessed Aug 12, 2008.

2 Kirkpatrick J, Lalman D. Foot rot in grazing cattle. Oklahoma State University. Oklahoma Cooperative Extension Service AMSI-3355. Available at: http://pods.dasnr.okstate.edu/docushare/dsweb/Get/Document-2023/ANSI-335.... Accessed Aug 27, 2008

All brands are the property of Pfizer Inc., its affiliates and/or its licensors. ©2008 Pfizer Inc. All rights reserved. GCA08028

Pfizer, Inc. • 150 East 42nd Street • New York, NY 10017

212-733-2323 • www.PfizerAH.com

For further information, contact:

Benjamin Church

Pfizer Animal Health

212-733-6628

benjamin.church@pfizer.com

Jill Spiekerman-Carrothers

Martin|Williams

515-971-9613

j.spiekerman@martinwilliams.com

Sponsored Introduction Continue on to (or wait seconds) ×